Primary Care Diabetes pcd.2017.06.004

Clinical risk factors predicting genital fungal infections with sodium–glucose cotransporter 2 inhibitor treatment: The ABCD nationwide dapagliflozin audit

Ken Yan Thong^a,∗, Mahender Yadagiri^b, Dennis Joseph Barnes^c, David Stuart Morris^d, Tahseen Ahmad Chowdhury^e , Ling Ling Chuah^f, Anthony Michael Robinson^g, Stephen Charles Bain^h, Karen Ann Adamsonⁱ, Robert Elford John Ryder^b, ABCD Nationwide Dapagliflozin Audit contributors¹

^aSchool of Medicine and Pharmacology, University of Western Australia, Perth, Australia

^bDepartment of Diabetes, Endocrinology and Lipid Metabolism, City Hospital, Birmingham, UK

^cDiabetes/Endocrinology Services, The Tunbridge Wells Hospital, Pembury, UK

^dBridgnorth Medical Practice, Northgate Health Centre, Shropshire, UK

^eDepartment of Diabetes, The Royal London Hospital, London, UK

^fCroydon Health Services NHS Trust, Croydon, UK

^gDepartment of Endocrinology, Royal United Hospitals, Bath, UK

^hAbertawe Bro Morgannwg University Board, Swansea, UK

ⁱDiabetes Department, St John’s Hospital, Livingston, UK